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The  recently  emerging  concept  of immunosuppression  developing  in  the ﬁeld  of  severe  sepsis  generated
the  need  to measure  circulating  immunoglobulins  as part  of the  necessary  tests  to evaluate  immunocom-
petence  status  in  patients  suffering  from  this  condition.  Serum  concentrations  can  be  used as a  surrogate
marker  of  the  ﬁnal  outcome  and  as  a  biomarker  to explore  the  need  for  supplementation  of the  host  with
intravenous  immunoglobulin  preparations.  Available  evidence  from  recent  clinical  studies  pinpoints  the
main  observations.  The  ﬁrst  is that  circulating  IgM  is a phenomenon  associated  with  progression  from
severe  sepsis  to septic  shock.  Deﬁcient  kinetics  of  circulating  IgM  during  the ﬁrst 7 days  following  the start
of  vasopressors  is linked  with  unfavourable  outcome.  The  second  is the  development  of immunoscores
using  low  levels  of  IgM,  IgG1 and  IgA.  These  immunoscores  can predict  28-day  mortality  with  an  odds
ratio  ranging  between  3 and  5. Novel  techniques  for  evaluating  patient’s  immune  status  are  shedding
new  light  on the  development  of modern  therapeutics  where  immunoglobulin  replacement  may  be  part
of a personalised  therapeutic  approach.
ublis© 2015  The  Authors.  P
. Introduction
Severe sepsis results as a failure of the immune system to
ontain an infection. In this case, the literature describes sev-
ral potential sequences of immunological events in patients with
epsis: those with predominant pro-inﬂammatory responses usu-
lly found when sepsis develops in a young, otherwise healthy
ndividual; those with predominant anti-inﬂammatory responses
sually developing in immunosuppressed individuals; those with
uctuating pro- and anti-inﬂammatory responses usually devel-
ping in healthy individuals where the infection source is not
dequately controlled; and those starting with concomitant pro-
nd anti-inﬂammatory responses followed by an impairment of
mmunocompetence status, which is the typical sequence of events
n the majority of patients [1]. Anti-inﬂammation is characterised
y failure of the immune system to respond adequately to a bacte-
ial stimulus. At that time course, lymphopenia predominates, part
f which involves B-lymphocytes and the subsequent capacity for
dequate production of immunoglobulins [2] (Fig. 1).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recognition of the existence of immunosuppression as a major
event in severe sepsis generated the concept that stimulation of
the immune response and/or replacement of key immunological
factors may  be a promising therapeutic strategy. Treatment with
immunoglobulins may  be part of that strategy. Although admin-
istration regimens consisting of immunoglobulins of the IgG class
failed to improve outcomes [3,4], a recent meta-analysis has shown
a considerable decrease in the relative risk of death due to severe
sepsis both in paediatric and adult populations with the admin-
istration of regimens enriched with immunoglobulins of the IgM
subclass [polyclonal IgG, IgM and IgA (IgGAM); Pentaglobin®] [5].
This developed the need to recognise those patients who  have
functional deﬁciency of IgM. Measurement of circulating levels of
immunoglobulins in the blood of patients may  be a biomarker to
distinguish patients with severe sepsis who  might beneﬁt from
IgGAM treatment. Several studies have been published over the
last 2 years monitoring the changes of circulating immunoglobulin
subclasses in severe sepsis and the relationship with ﬁnal outcome.
2. Circulating immunoglobulins as biomarkers in sepsisMeasurement of immunoglobulins in serum or plasma in
severe sepsis has appeared in the medical literature since 2009.
They include a total of seven publications [6–12], most of them
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. Major factors and events inﬂuencing the role of endogenous immunoglobulins in sepsis. Absence/presence of previous memory responses of B-cells and IgG against
the  infecting microbe could inﬂuence infection control. In addition, the presence of a previous status of immunodeﬁciency could impair immunoglobulin production affecting
their  levels in blood. When sepsis is already established, the three major immunoglobulin isotypes show a synergistic beneﬁcial effect on the risk of mortality, with non-
survivors showing lowers levels of immunoglobulins. A maintained distribution of IgM along time translates into improved outcomes. Beneﬁcial effects of endogenous
immunoglobulins include potential antimicrobial and immunomodulatory activities. During sepsis, immunoglobulin consumption is thought to occur (due to formation of
immune complexes with microbial antigens or oxidation products, or unspeciﬁc binding to leucocyte receptors). The presence of quantitative and functional depression
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if  the adaptive immunity observed in severe sepsis (which is more acute in non
icrobe and preclude maintaining adequate immunoglobulin levels along the disea
o  non-survivors. (For interpretation of the references to color in this ﬁgure legend,
ppearing in the last 2 years [8–12]. These publications refer to
tudies of measurements of immunoglobulins levels in severe sep-
is and septic shock or in severe pneumonia and to studies of the
inetics of IgM in sepsis.
.1. Immunoglobulin levels in severe sepsis and septic shock
The ﬁrst small study enrolled 21 patients with septic shock; 16
ad hypogammaglobulinaemia. These patients could be classiﬁed
nto those with selectively low IgG, those with selectively low IgM
nd those with combined low IgG and IgM. Of the 21 patients, 6
28.5%) died [6]. In the next study on 62 septic shock patients, cir-
ulating IgG, IgA and IgM were measured on Days 1–2, 3–4 and 5–7
f the course of septic shock. IgG and IgM were below the levels of
ealthy controls particularly on Days 1–2 and Days 3–4; a similar
ecrease was not found for IgA. During the start of septic shock,
1% of patients had low IgG, 40% of patients had low IgM and 4% of
atients had low IgA [7]. Shankar-Hari et al. have recently reviewed
he available evidence on the association between endogenous IgG
evels and outcome in patients with severe sepsis or septic shock
13]. This meta-analysis found that the prevalence of IgG hypogam-
aglobulinaemia on the day of sepsis diagnosis was as high as 70%
n heterogeneous sepsis cohorts reporting different lower limits
f normality for IgG. None the less, based upon the results of this
eview, a single subnormal measurement of IgG on the day of sep-
is diagnosis would not be useful to identify a subgroup of patients
ith a higher risk of death.
In our view, the answer could be in considering immunoglobulin
sotypes not as isolated entities but in evaluating their prognosticvors) could in turn impair production of speciﬁc antibodies against the infecting
urse. APC, antigen-presenting cell; ICU, intensive care unit. Red colour corresponds
ader is referred to the web version of this article.)
ability in combination. In a recent multicentre prospective study
from nine hospitals in Spain, IgG, IgA and IgM were measured
in 172 patients at the time of diagnosis of severe sepsis or sep-
tic shock [8]. In that study, categorical variables were used to
develop immunoscores predictive of ﬁnal outcome. A cut-off of
the measured level of each immunoglobulin was identiﬁed based
on the impact of individual immunoglobulin isotypes and sub-
classes on mean survival time, and each patient was classiﬁed as of
low or high level for each immunoglobulin according to this cut-
off. The cut-offs were 300 mg/dL for IgG1, 35 mg/dL for IgM and
150 mg/dL for IgA. Admission concentrations below each of these
cut-offs were predictive of unfavourable outcome. The ﬁrst inter-
esting ﬁnding was that these cut-offs were well below the range
of hypogammaglobulinaemia for IgG and IgM. As a consequence,
the concept of hypogammaglobulinaemia deﬁned as ‘subnormal
levels of immunoglobulins’ appears to be no use in sepsis, where
real biological cut-offs inﬂuencing patient outcomes are needed.
When these cut-offs were combined using logistic regression anal-
ysis, it was  found that three immunoscores were signiﬁcantly
associated with unfavourable outcome: (i) all three IgG1, IgM and
IgA below the cut-offs [odds ratio (OR) = 5.27]; (ii) both IgG1 and
IgM below the cut-offs (OR = 3.10); and (iii) both IgG1 and IgA
below the cut-offs (OR = 4.10) [8]. The prevalence of patients with
previous immunosuppression was 20% in this cohort. As a con-
sequence, the presence of this condition in patients with sepsis
should be taken into account in the design of clinical trials with
intravenous immunoglobulin (IVIg), since these patients should
potentially constitute a priority regarding treatment indication.
Our group is working in developing new immunoscores based on
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mmunoglobulin levels, and new data are emerging supporting the
ynergy of total IgG, IgA and IgM regarding mortality prediction in
evere sepsis.
.2. Kinetics of IgM in sepsis
The largest study conducted so far on the kinetics of IgM in sepsis
s that from the Hellenic Sepsis Study Group (http://www.sepsis.gr)
nrolling 332 critically ill patients from 27 study sites; 41 were clas-
iﬁed as sterile systemic inﬂammatory response syndrome (SIRS)
ue to acute pancreatitis, 100 as uncomplicated sepsis, 113 as
evere sepsis and 78 as septic shock using internationally well
ccepted deﬁnitions; in addition, 35 healthy controls were studied.
irculating IgM was measured within the ﬁrst 24 h from diagno-
is and were signiﬁcantly higher in controls, patients with SIRS
nd patients with severe sepsis than in patients with septic shock.
urprisingly, circulating IgM in uncomplicated sepsis did not dif-
er from septic shock. Measurements were repeated for 83 patients
ho worsened. A decrease of IgM was found only in the case of
ransition from severe sepsis into septic shock. Finally, serum IgM
as measured at presentation of septic shock and for another 6
onsecutive days in 30 patients. The time of initiation of adminis-
ration of vasopressors was the start point for measurements. The
rea under the curve of IgM over the entire time of follow-up (7
ays) was measured separately for survivors and non-survivors. It
as considered that this area represented the body distribution
f IgM. The area was signiﬁcantly larger in survivors than in non-
urvivors both when censoring was done on Day 28 and on the day
f hospital discharge [11].
A salient feature of this study was the isolation of peripheral
lood mononuclear cells from patients and their stimulation with
he lymphocyte agonist phytohaemagglutinin for the production
f IgM. Low IgM production was a common characteristic of all
tages of sepsis compared with healthy controls and it was  more
ronounced in severe sepsis and septic shock. These ﬁndings, in
onjunction with the reported kinetics of circulating IgM, led to
he hypothesis that suppression of B-lymphocytes supervenes in
evere sepsis and septic shock. However, serum IgM remains at
igh levels in severe sepsis and it is consumed upon worsening
nto septic shock. Survival is probably linked with the ability of
he host to maintain adequate body distribution of IgM [11]. IgM
lays an important role in the clearance of oxidation-speciﬁc epi-
opes and, as a consequence, may  provide a generalised protective
esponse against the consequences of oxidative stress produced in
he context of critical illness [14].
It should be underscored that the primary endpoint of all
f the above studies was the association between endogenous
mmunoglobulin levels and mortality. This is in contrast with cur-
ent trials on the administration of IVIg in severe infections such
s community-acquired pneumonia that consider softer endpoints
uch as days of mechanical ventilation, days of hospitalisation and
ays in the intensive care unit (ICU) [15].
. Commentary
Acquired knowledge over the last years has shown that early
easurements of circulating immunoglobulins may be used as a
urrogate marker of unfavourable outcome in severe sepsis as well
s the need for replacement of immunoglobulins to reverse the
ourse of the patient. The concept is based on the assumption
hat lack of immunoglobulins renders a critically ill patient prone
o unfavourable outcome. This concept is further supported by a
ecently published prospective study on 90 critically ill patients
dmitted without infection to the ICU; those with admission levels
f IgM of <58 mg/dL had an unfavourable outcome [12].
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The developed immunoscores of severe sepsis linking admission
levels of low IgG1, low IgA and low IgM with unfavourable outcome
generate the hypothesis that early administration of a regimen con-
taining all three classes of immunoglobulins, such as IgGAM, may
be effective. This hypothesis is compatible with evidence from a
retrospective analysis of 129 patients with septic shock who  were
treated with IgGAM; survival beneﬁt was associated with early start
of treatment within the ﬁrst 23 h [16].
Finally, endogenous immunoglobulins should not be considered
as isolated elements of the immune system. Profound alterations
in both innate and adaptive arms of the immune response are
observed in cases of severe sepsis [17]. Real-time PCR and emerg-
ing technologies such as droplet digital PCR or next-generation
sequencing [18] could help to obtain a wider picture of the patient’s
immune status. At the same time, it is necessary to know more
about the biological effects of immunoglobulins in sepsis, i.e.
antimicrobial or immunomodulatory [19]; evaluating the inﬂuence
on patient outcome of previous speciﬁc IgG antibodies against the
infecting microbe, or identifying the inﬂammatory targets modu-
lated by IgM are two  examples. Integrating immunoglobulin levels
with this complementary information could help to better under-
stand the role of the former in sepsis.
Despite the need for randomised controlled trials, the above
accumulating evidence clearly opens new perspectives for the use
of circulating immunoglobulins as a surrogate market to deﬁne the
best candidates for treatment with intravenous IgGAM. Consider-
ations commented in these article could help to clarify the role of
endogenous immunoglobulins in sepsis as well as to improve the
results of trials employing IVIg for the treatment of sepsis.
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